comparemela.com

Page 59 - Nvo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Qualcomm, PayPal, SolarEdge, Roku, DoorDash, and More Stock Market Movers

Qualcomm’s fiscal first-quarter forecast tops estimates, Starbucks posts quarterly profit better than expectations, PayPal raises its full-year earnings.

Jerome powellFederal reserveChairman jerome powellArticle normalAgricultural machineryPortable power toolsRecreational boatsPrinting publishingNewspaper publishingLodgings restaurants barsRestaurants caterersLimited service restaurantsComputer servicesIt support servicesBusiness consumer servicesBanking credit

Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies

Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.

United statesNovo nordiskNorth americaEli lillyArticle normalAgricultural machineryHealthcare life sciencesIndustrial goodsFinancial performanceSales figuresCorporate industrial newsPolitical general newsPhysical mental fitnessLiving lifestyleWeight managementContent types

Eli Lilly Stock Slumps as Earnings Guidance Slashed Dramatically

Lilly cuts its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.

Versanis bioJack dentonEli lillyNovo nordiskArticle normalBiotechnology servicesAgricultural machineryHealthcare life sciencesIndustrial goodsFinancial performanceCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterEarnings reportBiotech and pharma

Vertex Pain Pill Could Replace Opioids It s an Opportunity for Investors

The new Vertex pain pill is in trials now. Investors might want to make their bets soon.

United statesSan diegoLeerink risingerSalveen richterDavid risingerJosh nathan kazisChoi chanStephen waxmanMarks wallaceRegeneron pharmaceuticalsUniversity of californiaDrug administrationGoldman sachsVertex pharmaceuticalsLeerink partnersEli lilly

Eli Lilly Stock Drops After Earnings Its Guidance Disappoints

Lilly cuts its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.

Eli lillyJack dentonVersanis bioDavida ricksNovo nordiskArticle normalBiotechnology servicesAgricultural machineryHealthcare life sciencesIndustrial goodsFinancial performanceCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterEarnings report

vimarsana © 2020. All Rights Reserved.